PIT565

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Rheumatoid ArthritisSystemicB-Cell Non-Hodgkin Lymphoma (b-NHL)

176 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

1

Actos

Takeda

Preclinical

22

Celexa

AbbVie

Preclinical

13

Plaquenil

Jazz Pharmaceuticals

Preclinical

—4

Voltaren

Novartis

Preclinical

—5

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

26

Velcade

SShilpa Grover, MD, MPH

Preclinical

27

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

18

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Valium

Akero Therapeutics

Preclinical

—Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

B-cell Non-Hodgkin Lymphoma (B-NHL)1 trial

A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies

Active, not recruiting·Novartis·Phase 1·NCT05397496·61 enrolled

Systemic1 trial

A Phase Ib, Open-label, Ascending Dose Study With Step-up Doses to Assess Safety, Tolerability, and Pharmacokinetics of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Active, not recruiting·Novartis·Phase 1·NCT06335979·54 enrolled

Rheumatoid Arthritis1 trial

A Phase Ib, Open-label, Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of PIT565 in Participants With Rheumatoid Arthritis (RA)

Active, not recruiting·Novartis·Phase 1·NCT07029555·57 enrolled

Details

Drug Info

Related News